Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets
29 Februar 2024 - 7:00PM
Business Wire
Eurofins Discovery, an industry-leading provider of products and
services for drug discovery research, today announced the launch of
DiscoveryAI SAFIRE (Suite of
ADMET Predictions
For In Silico Refinement and Evaluation). SAFIRE is an advanced platform
that leverages proprietary datasets, artificial intelligence (AI),
and machine learning (ML), offering a unique capability for
expediting discovery. SAFIRE is now available for customer use
through the Eurofins Discovery website.
Eurofins Discovery’s experienced informatics experts collected
vast, high-quality and diverse datasets that provide a unique
approach in predicting the ADMET (Absorption, Distribution,
Metabolism, Excretion and Toxicity) properties of molecules. It
sets a new standard in predictive analytics.
SAFIRE utilizes data from Eurofins Discovery’s preeminent
BioPrint database, curated over years of meticulous research and
data accumulation. The result: a more powerful research tool
surpassing the limits that exist in other predictive systems
currently in the market, as demonstrated in a recent publication in
the Future Medical Chemistry journal.
Designed with end-users in mind, SAFIRE provides essential
features such as scoring functionality to aid in decision-making
and a comprehensive suite of predictive ADME models. It’s proven
effective in accelerating drug discovery projects from initial hit
discovery through to lead optimization.
How does SAFIRE go beyond existing predictive system limits in
the market? Published results of our AI advances demonstrated how
our models can be used to predict ADMET properties of molecules
quickly and efficiently, when trained with BioPrint database
proprietary data along with public datasets utilized by the SAFIRE
platform. This approach has proven improved model performance as
well as broadened the chemical space covered by the models,
achieving Matthews Correlation Coefficient values greater than 0.4,
and accuracies above 80%.
Eurofins Discovery’s experts keep SAFIRE dynamic with consistent
updates, enlargements of its chemical space, and the latest in AI
and ML innovations. For more details about SAFIRE’s benefits and
significant value to the drug discovery community, visit
eurofinsdiscovery.com/safire.
About Eurofins Discovery
Eurofins Discovery supports drug discovery research with over
23,000 products and services developed in 40+ years of industry
leadership. Benefit from the strength of our solutions that
revolutionize your drug discovery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229279233/en/
Media: Aida Yodites, Director, Marketing Communications
aida.yodites@discovery.eurofinsus.com
Luis Miguel Goncalves, Senior Director, IT & Informatics
LuisMiguelGoncalves@eurofinsUS.com
Enerplus (NYSE:ERF)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
Von Mai 2023 bis Mai 2024